Viking Therapeutics stock sinks after mixed results from its obesity pill trial, raising doubts over safety, tolerability and ...

We recently published 10 Big Names With Surprising Gains. Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of Wednesday’s best performers. Viking Therapeutics bounced back by 5.46 percent on Wednesday ...

The oral formulation led to up to 12.2% weight loss over three months, a weaker outcome versus late-stage treatments from Eli ...

Viking Therapeutics (VKTX) shares crashed nearly 29% in todays trade after the companys much-anticipated weight-loss pill ...

Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra ...

Viking Therapeutics (VKTX) stock drops as its oral obesity drug VK2735 trails Novo's (NVO) oral Wegovy and Lilly's (LLY) ...

When bad news drops, investors have a tendency to sell first and ask questions later. Let's take a closer look at why Viking ...

Viking Therapeutics reported positive Phase 2 results for VK2735, showing significant weight loss and safety in obesity ...

The clinical-stage biopharmaceutical firm, Viking Therapeutics, Inc. (NASDAQ:VKTX), based in San Diego, develops novel ...

Viking Therapeutics ( (VKTX) ) has provided an announcement.

Viking shares fell on Phase 2 obesity pill data as tolerability issues surfaced, but William Blair says the stock's sell-off ...

Shares of San Diego, USA-based Viking Therapeutics tumbled 43% to $23.50 by mid-morning after the company released mid-stage ...